| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | 用于治疗和/或预防天然AHR配体依赖性癌症的手段和方法 | CN201280043522.9 | 2012-09-07 | CN104023713A | 2014-09-03 | M·普拉滕; C·奥皮茨; W·维克; U·利岑贝格 |
| 本发明涉及癌症疗法和癌症治疗的领域。特别地，本发明涉及用于治疗和／或预防天然AHR配体依赖性癌症的方法，其包括向患有所述癌症的受试者施用治疗有效量的AHR抑制剂。而且，本发明还涉及AHR抑制剂用于治疗和／或预防天然AHR配体依赖性癌症。 | ||||||
| 2 | VACCINE COMPOSITIONS COMPRISING TRYPTOPHAN 2,3-DIOXYGENASE OR FRAGMENTS THEREOF | US15509443 | 2015-09-15 | US20170239337A1 | 2017-08-24 | Mads Hald Andersen |
| The invention relates to prophylaxis and therapy of cancer. In particular there is provided a protein Tryptophan2,3-di-oxygenase (TDO) or peptide fragments here of that are capable of eliciting anti-cancer immune responses. Specifically, the invention relates to the use of TDO or peptides derived thereof or TDO specific T-cells for treatment of cancer. The invention thus relates to an anti-cancer vaccine which optionally may be used in combination with other immunotherapies and to TDO specific T-cells adoptively transferred or induced in vivo by vaccination as a treatment of cancer. It is an aspect of the invention that the medicaments herein provided may be used in combination with cancer chemotherapy treatment. A further aspect relates to the prophylaxis and therapy of infections by the same means as described above. | ||||||
| 3 | Means and methods for treating and/or preventing natural AHR ligand-dependent cancer | US14343350 | 2012-09-07 | US09593062B2 | 2017-03-14 | Michael Platten; Christiane Opitz; Wolfgang Wick; Ulrike Litzenburger |
| The present invention relates to the field of cancer therapeutics and treatment of cancer. In particular, it relates to a method for treating and/or preventing a natural AHR ligand-dependent cancer comprising administering to a subject suffering from said cancer a therapeutically effective amount of an AHR inhibitor. Moreover, contemplated is a AHR inhibitor for use in treating and/or preventing a natural AHR ligand-dependent cancer. | ||||||
| 4 | MEANS AND METHODS FOR TREATING AND/OR PREVENTING NATURAL AHR LIGAND-DEPENDENT CANCER | US14343350 | 2012-09-07 | US20140294860A1 | 2014-10-02 | Michael Platten; Christiane Opitz; Wolfgang Wick; Ulricke Litzenburger |
| The present invention relates to the field of cancer therapeutics and treatment of cancer. In particular, it relates to a method for treating and/or preventing a natural AHR ligand-dependent cancer comprising administering to a subject suffering from said cancer a therapeutically effective amount of an AHR inhibitor. Moreover, contemplated is a AHR inhibitor for use in treating and/or preventing a natural AHR ligand-dependent cancer. | ||||||
| 5 | トリプトファン２，３−ジオキシゲナーゼまたはそのフラグメントを含むワクチン組成物 | JP2017514626 | 2015-09-15 | JP2017533182A | 2017-11-09 | ホールド アンデルセン，マッズ |
| 本発明は癌の予防法および治療法に関する。具体的には、抗癌免疫応答を誘発することが可能なタンパク質のトリプトファン2,3−ジオキシゲナーゼ(TDO)またはそのペプチドフラグメント提供される。具体的には、本発明は、TDOもしくはそれに由来するペプチドまたはTDO特異的T細胞の癌治療への使用に関する。したがって、本発明は、癌治療としての任意選択で他の免疫療法と併用し得る抗癌ワクチンおよび養子移植するかワクチン接種によってin vivoで誘導されるTDO特異的T細胞に関する。本明細書に提供される薬物を癌の化学療法と併用し得ることは本発明の一態様である。さらなる態様は、上記のものと同じ手段による感染症の予防法および治療法に関するものである。【選択図】なし | ||||||
| 6 | NANOPLATFORMS FOR ARGINASE, INDOLEAMINE 2,3-DIOXYGENASE AND TRYPTOPHAN 2,3-DIOXYGENASE DETECTION BY POSTTRANSLATIONAL MODIFICATION | US15559543 | 2016-03-18 | US20180099057A1 | 2018-04-12 | Stefan H. Bossmann; Deryl L. Troyer; Aruni P. Malalasekera; Hongwang Wang; Sebastian O. Wendel; Gaohong Zhu |
| A nanoplatform assembly for detection of arginase, indoleamine 2,3-dioxygenase 1, and/or tryptophan 2,3-dioxygenase. The nanoplatform comprises an oligopeptide, which is used as a linker between two particles. More preferably, the linker is comprised of an oligopeptide containing a substrate for the target enzyme, where the substrate is chemically or physically modified by the target enzyme (but not cleaved). A central particle with a plurality of oligopeptide-tethered detectable particles and a plurality of directly attached detectable particles is described. Posttranslational modification of the oligopeptide leads to changes in the detectable signals from the first and/or second particles in the nanoplatform, which can be correlated to enzyme activity and concentration. | ||||||
| 7 | Kynurenine Pathway Biomarkers Predictive of Anti-Immune Checkpoint Inhibitor Response | US15036892 | 2014-11-20 | US20160299146A1 | 2016-10-13 | Levi Garraway; Marios Giannakis; Grigoriy V. Kryukov |
| The present invention is based on the identification of novel biomarkers predictive of responsiveness to anti-immune checkpoint inhibitor therapies. | ||||||
| 8 | Treatment of bone diseases | US14344702 | 2012-09-13 | US09642897B2 | 2017-05-09 | Gustavo Duque; Christopher Vidal |
| The invention relates generally to the field of bone diseases. More specifically, the invention relates to methods and compositions for the treatment of osteoporosis and related disorders. | ||||||
| 9 | TREATMENT OF BONE DISEASES | US14344702 | 2012-09-13 | US20150343037A1 | 2015-12-03 | Gustavo Duque; Christopher Vidal |
| The invention relates generally to the field of bone diseases. More specifically, the invention relates to methods and compositions for the treatment of osteoporosis and related disorders. | ||||||
| 10 | Method of cancer treatment using siRNA silencing | US11917593 | 2006-06-15 | US08389708B2 | 2013-03-05 | Weiping Min |
| The present invention is a method for the treatment of cancer involving tumor derived immunosuppression in a subject. The method comprises administering to a subject one or more siRNA constructs capable of inhibiting the expression of an immunosuppressive molecule. The invention also provides siRNA constructs and compositions. | ||||||
| 11 | METHOD OF CANCER TREATMENT USING SIRNA SILENCING | US11917593 | 2006-06-15 | US20090220582A1 | 2009-09-03 | Weiping Min |
| The present invention is a method for the treatment of cancer involving tumor derived immunosuppression in a subject. The method comprises administering to a subject one or more siRNA constructs capable of inhibiting the expression of an immunosuppressive molecule. The invention also provides siRNA constructs and compositions. | ||||||
| 12 | Tourette syndrom, autism and associated behaviors | US562596 | 1990-08-03 | US5405943A | 1995-04-11 | David E. Comings |
| The human tryptophan oxygenase gene sequence and chromosomal location are described. Procedures for the diagnosis of genetic Tourette syndrome and many psychiatric and behavioral disorders by genetic tests to identify deletions or defective alleles in the human tryptophan oxygenase (TO) gene and cDNA probes for use in such tests are also described. | ||||||
| 13 | Method for the diagnosis of Tourette syndrome and associated disorders | US715660 | 1991-06-14 | US5260196A | 1993-11-09 | David E. Comings |
| Differences in the rate of kynurenine formation in the lysates of red blood cells of a patient suspected of having Tourette syndrome, Tourette syndrome associated disorders or Tourette spectrum disorders and of a control are used for the diagnosis of such disorders. | ||||||
| 14 | 天然AHRリガンド依存性癌を治療および/または予防するための手段および方法 | JP2014528990 | 2012-09-07 | JP6047160B2 | 2016-12-21 | プラッテン,ミヒャエル; オピッツ,クリスティアーネ; ヴィック,ヴォルフガング; リッツェンブルガー,ウルリケ |
| 15 | Means and methods for treating natural ahr ligand-dependent cancers and / or prophylaxis | JP2014528990 | 2012-09-07 | JP2014526450A | 2014-10-06 | プラッテン，ミヒャエル; オピッツ，クリスティアーネ; ヴィック，ヴォルフガング; リッツェンブルガー，ウルリケ |
| 本発明は、癌治療学および癌治療の分野に関する。 より詳細には、本発明は、天然AHRリガンド依存性癌を治療および/または予防するための方法に関するが、その方法は、前記癌に罹患した被験体に、治療上有効な量のAHR阻害剤を投与することを含む。 さらに、天然AHRリガンド依存性癌の治療および/または予防に用いるAHR阻害剤を検討する。
【選択図】なし |
||||||
| 16 | MEANS AND METHODS FOR TREATING AND/OR PREVENTING NATURAL AHR LIGAND-DEPENDENT CANCER | EP12758452.2 | 2012-09-07 | EP2753315B1 | 2017-03-01 | PLATTEN, Michael; OPITZ, Christiane; WICK, Wolfgang; LITZENBURGER, Ulrike |
| 17 | DIAGNOSTIC TESTS FOR TOURETTE SYNDROME AND RELATED BEHAVIORS | EP91916536.0 | 1991-08-02 | EP0495090A1 | 1992-07-22 | COMINGS, David, E. |
| L'invention concerne des tests qui permettent d'analyser ou de déterminer l'intégrité fonctionnelle du tryptophane 2,3-dioxygénase, IDO2 dans la relation avec le syndrome de Tourette et des troubles associés. Des tests de diagnostic sont également décrits pour diagnostiquer le syndrome de Tourette et des comportements apparentés. | ||||||
| 18 | IMMUNOSUPPRESSION-REVERTING OLIGONUCLEOTIDES INHIBITING THE EXPRESSION OF TDO | EP17150683.5 | 2017-01-09 | EP3346007A1 | 2018-07-11 | Klar, Richard; Jaschinski, Frank |
The present invention refers to an immunosuppression-reverting oligonucleotide hybridizing with a nucleic acid sequence of tryptophan-2,3-dioxygenase (TDO) and a pharmaceutical composition comprising such immunosuppression-reverting oligonucleotide and a pharmaceutically acceptable carrier, excipient and/or diluent. The oligonucleotide and the pharmaceutical composition, respectively, is used in a method for preventing and/or treating an autoimmune disorder, an immune disorder, a psychiatric disorder and/or cancer.
|
||||||
| 19 | METHOD OF CANCER TREATMENT USING SIRNA SILENCING | EP06761058 | 2006-06-15 | EP1898936A4 | 2009-05-06 | MIN WEIPING |
| The present invention is a method for the treatment of cancer involving tumor derived immunosuppression in a subject. The method comprises administering to a subject one or more siRNA constructs capable of inhibiting the expression of an immunosuppressive molecule. The invention also provides siRNA constructs and compositions. | ||||||
| 20 | 천연 AHR 리간드-의존성 암을 치료 및/또는 예방하기 위한 수단 및 방법 | KR1020147009041 | 2012-09-07 | KR1020140074330A | 2014-06-17 | 플라텐,마이클; 오피츠,크리스티앙; 뷕,볼프강; 릿젠버거,율리케 |
| 본 발명은 암의 치료 및 암의 처치 분야에 관한 것이다. 특히, 치료학적으로 유효량의 AHR 억제제를 상기 암으로부터 고통받는 대상에 투여하는 단계를 포함하는 천연 AHR 리간드-의존성 암을 치료 및/또는 예방하기 위한 방법에 관한 것이다. 더욱이, 천연 AHR 리간드-의존성 암을 치료 및/또는 예방에서 사용하기 위한 AHR 억제제는 고려된다.
|
||||||
QQ群二维码
意见反馈
意见反馈